SecBot SecBot
Biotech Drug Report Generated Jul 8, 2026

VIVITROL

ALKS·Alkermes plc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already marketed (FDA-approved 2006 for alcohol dependence; 2010 for opioid dependence)
Why 4/10
VIVITROL is already FDA-approved and marketed with no pending regulatory decision (PDUFA or pivotal readout) for this drug. The next hard catalyst is the scheduled Teva generic entry on January 15, 2027 (~6 months away), a known revenue headwind rather than a binary event. VIVITROL accounts for ~29% of Alkermes' $1.56B total revenue, but the company is diversifying (LUMRYZ, alixorexton, ARISTADA, LYBALVI), so this single drug is no longer make-or-break.
Actionable Insight NEUTRAL

Watch for the January 2027 Teva generic entry, this will pressure Vivitrol's ~$457M annual revenue stream. Monitor the antitrust lawsuit (Value Drug, filed Oct 2025) which could accelerate generic competition. The stock has run ~97% from its 52-week low and trades near its high; consider whether the diversification story (LUMRYZ, alixorexton orexin agonist in Phase 3) adequately offsets the Vivitrol cliff.

Price Chart

Loading chart...

Executive Summary

VIVITROL (extended-release injectable naltrexone) is Alkermes' flagship commercial product, generating $457.3M in 2024 revenue (14% YoY growth, ~29% of Alkermes' total revenue). FDA-approved since 2006 for alcohol dependence and 2010 for opioid dependence, it is a once-monthly opioid antagonist injection that reduces cravings. Its key overhang is the January 2027 Teva generic entry, established by a 2023 patent settlement. An October 2025 antitrust lawsuit alleges Alkermes illegally blocked generic competition. Alkermes is actively diversifying via the Avadel/LUMRYZ acquisition and advancing alixorexton (orexin agonist) in Phase 3 for narcolepsy, reducing Vivitrol's singular importance to the investment thesis.

How It Works

VIVITROL is a once-monthly injection of naltrexone, a drug that blocks opioid receptors in the brain. This reduces cravings for alcohol and opioids and prevents the euphoric "high" if someone relapses, helping patients maintain sobriety. Unlike methadone or buprenorphine, it is not an opioid itself and has no abuse potential.

Trial Status

VIVITROL is an approved commercial product with no active pivotal trials. Teva has a license to launch a generic version beginning January 15, 2027 per an August 2023 settlement agreement.

The Two-Sided Case

▲ Bull Case4
VIVITROL net sales grew 14% YoY to $457.3M in 2024, with Q4 2024 up 31% YoY to $134.1M, still growing nicely as a mature product (source: investor.alkermes.com).
Alkermes is diversifying away from Vivitrol concentration: ARISTADA ($346M), LYBALVI ($280M), and the newly acquired LUMRYZ (sleep/narcolepsy) plus alixorexton orexin agonist pipeline reduce single-drug dependence (source: marketscreener.com).
Analyst consensus remains broadly bullish with 19 buy/strong-buy ratings, mean price target ~$50.19, with multiple firms (Mizuho, Needham, TD Cowen, RBC) maintaining Outperform/Buy.
The Teva generic entry (Jan 2027) is a known, scheduled event, already priced in by the market to some degree; Alkermes has time to transition revenue mix.
▼ Bear Case5
Teva licensed to launch a generic version of Vivitrol beginning January 15, 2027, this will significantly erode ~$457M in annual revenue, a ~29% chunk of Alkermes' total (source: fiercepharma.com, PRNewswire).
Antitrust class-action lawsuit filed Oct 2025 by Value Drug alleging Alkermes illegally blocked generic competition could accelerate generic entry or result in financial penalties (source: Reuters, JDJournal).
Consistent insider selling: multiple executives (CMO Hopkinson, EVP Gaffin, Director Wright) sold shares throughout 2026, mostly via 10b5-1 plans but signaling limited insider conviction at current elevated prices.
Stock trades at $55.22 near its 52-week high ($55.67) with RSI 76.5 (overbought); B of A Securities downgraded to Underperform in June 2026.
Short interest was elevated in late June 2026 (short ratios of 60-71%), suggesting bearish bets have been accumulating (source: FINRA short volume data).

Upcoming Catalysts

  • January 15, 2027: Teva generic VIVITROL launch (known, scheduled event)
  • Ongoing: Antitrust class-action lawsuit (Value Drug), any summary judgment or settlement could accelerate resolution
  • Q3/Q4 2026 & early 2027: Alixorexton Phase 3 narcolepsy data readouts (key for Alkermes diversification thesis)
  • Quarterly earnings: Vivitrol revenue trajectory as generic entry approaches

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Alkermes plc. 8-K ALKS ·Originating report

Sources · 11

Hover a chip for the title
1 drugs.com2 investor.alkermes.com3 marketscreener.com4 fiercepharma.com5 reuters.com6 prnewswire.com7 panabee.com8 drugstorenews.com9 accessdata.fda.gov10 sec.gov11 sec.gov